/RECEF
RECEF Stock - Recce Pharmaceuticals Ltd
Healthcare|BiotechnologyOTC
$0.22+0.00%
+$0.00 (+0.00%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.24
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RECEF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.22 – $0.22
TARGET (TP)$0.25
STOP LOSS$0.20
RISK/REWARD1:1.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.18
52W High$0.60
52W Low$0.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $7.51M | $6.85M | $4.37M | $3.08M | $1.64M |
| Gross Profit | $-2,937,489 | $-366,768 | $4.15M | $2.90M | $1.34M |
| Gross Margin | -39.1% | -5.4% | 95.0% | 93.9% | 81.9% |
| Operating Income | $-22,880,440 | $-22,051,237 | $-17,325,560 | $-14,150,300 | $-15,364,480 |
| Net Income | $-21,428,089 | $-17,661,714 | $-13,077,422 | $-10,986,277 | $-13,513,366 |
| Net Margin | -285.4% | -257.8% | -299.6% | -356.1% | -825.3% |
| EPS | $-0.09 | $-0.10 | $-0.07 | $-0.06 | $-0.09 |
Company Overview
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
RECEFBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.02
Q3 2024
EPS Surprise History
Q3 22
No data
Q4 22
No data
Q1 23
No data
Q2 23
No data
Q1 24
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | — | — | — | — |
Q2 2025 | Apr 30, 2025 | — | — | — | — |
Q1 2025 | Feb 25, 2025 | — | — | — | — |
Q4 2024 | Oct 31, 2024 | — | — | — | — |
Q3 2024 | Aug 30, 2024 | — | $-0.02 | — | — |
Q2 2024 | Apr 22, 2024 | — | $-0.02 | — | — |
Q1 2024 | Feb 27, 2024 | — | $-0.01 | — | — |
Q1 2024 | Jan 29, 2024 | — | $-0.01 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.01 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.01 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.02 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.02 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about RECEF
What is RECEF's current stock price?
Recce Pharmaceuticals Ltd (RECEF) is currently trading at $0.22 per share. The stock has moved +0.00% today.
What is the analyst price target for RECEF?
No analyst price targets are currently available for this stock.
What sector is Recce Pharmaceuticals Ltd in?
Recce Pharmaceuticals Ltd operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is RECEF's market cap?
Recce Pharmaceuticals Ltd has a market capitalization of $0.08 billion, making it a small-cap company.
Does RECEF pay dividends?
No, Recce Pharmaceuticals Ltd does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADOCY
Adocia S.A.
$11.80
Mkt Cap: $0.2B
ADOIF
Adocia S.A.
$8.87
Mkt Cap: $0.1B
AMCY
ACS Global, Inc.
$3.00
Mkt Cap: $0.2B
AMGXF
AnGes, Inc.
$0.36
Mkt Cap: $0.1B
BRNHF
Broncus Holding Corporation
$0.08
Mkt Cap: $0.0B
EKDHF
EKF Diagnostics Holdings plc
$0.30
Mkt Cap: $0.1B
EPRXF
Eupraxia Pharmaceuticals Inc.
$3.04
Mkt Cap: $0.1B
FPHAF
Faron Pharmaceuticals Oy
$3.30
Mkt Cap: $0.2B
PLNHF
Planet 13 Holdings Inc.
$0.91
Mkt Cap: $0.2B
PSTTF
Prescient Therapeutics Limited
$0.14
Mkt Cap: $0.1B
Explore stocks similar to RECEF for comparison